Literature DB >> 12117589

D1 and D2 dopamine receptors contribute to the locomotor response induced by Group II mGluRs activation in the rat nucleus accumbens.

Nathalie Breysse1, Céline Risterucci, Marianne Amalric.   

Abstract

Whereas the involvement of ionotropic glutamate receptors (iGluRs) in the functional interaction between glutamate and dopamine (DA) systems in the nucleus accumbens (N. Acc.) is well established, the role of metabotropic glutamate receptors (mGluRs) is less clear. This study was thus aimed to investigate the mechanisms involving DA and glutamate systems via mGluRs in the generation of motor activity in rats. Intra-accumbens infusion of the Group II agonist (2S,3S,4S)-2-(carboxycyclopropyl)glycine (L-CCG-I; 25, 50, 100 nmol) increased locomotor activity, whereas the Group I agonist (S)-3,5-dihydroxyphenylglycine (S-3,5-DHPG) at the same doses had no effect. The effects of L-CCG-I were blocked by a selective Group II mGluRs antagonist (2S,3S,4S)-2-methyl-2-(carboxypropyl)glycine (MCCG; 50 nmol). The locomotor stimulant effect induced by L-CCG-I might be partly DA mediated, as it is abolished by a pretreatment with the DA receptor antagonist haloperidol (0.1 mg/kg ip) and potentiated by D-amphetamine systemic injection (0.5 mg/kg sc). Furthermore, selective D1 (SCH 23390; 0.005, 0.01 and 0.02 mg/kg) or D2 (raclopride; 0.05, 0.1 and 0.2 mg/kg) antagonists injected systemically were also effective in decreasing L-CCG-I induced hyperactivity. Taken together, these results demonstrate that stimulation of Group II but not Group I mGluRs contributes to the regulation of motor behavior in the N. Acc. and that this increased activity requires the activation of both D1 and D2 DA receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117589     DOI: 10.1016/s0091-3057(02)00851-1

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders.

Authors:  Mohammad-Reza Noori-Daloii; Majid Mojarrad; Ali Rashidi-Nezhad; Majid Kheirollahi; Ali Shahbazi; Mehdi Khaksari; Asghar Korzebor; Ali Goodarzi; Maryam Ebrahimi; Ali Reza Noori-Daloii
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

Review 2.  Common liability to addiction and "gateway hypothesis": theoretical, empirical and evolutionary perspective.

Authors:  Michael M Vanyukov; Ralph E Tarter; Galina P Kirillova; Levent Kirisci; Maureen D Reynolds; Mary Jeanne Kreek; Kevin P Conway; Brion S Maher; William G Iacono; Laura Bierut; Michael C Neale; Duncan B Clark; Ty A Ridenour
Journal:  Drug Alcohol Depend       Date:  2012-01-18       Impact factor: 4.492

3.  Dopamine-mediated MK-801-induced elevation in food-based extinction responding in rats and associated changes in region-specific phosphorylated ERK.

Authors:  Matthew R Holahan; Melanie J Clarke; Delaney D Hines
Journal:  Psychopharmacology (Berl)       Date:  2010-07-23       Impact factor: 4.530

4.  Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice.

Authors:  Yosuke Morishima; Tsuyoshi Miyakawa; Tomoyuki Furuyashiki; Yasuhiro Tanaka; Hiroshi Mizuma; Shigetada Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

5.  Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.

Authors:  Nathalie Breysse; Christelle Baunez; Will Spooren; Fabrizio Gasparini; Marianne Amalric
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

6.  Towards a reconceptualization of striatal interactions between glutamatergic and dopaminergic neurotransmission and their contribution to the production of movements.

Authors:  Hélène N David
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.